

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
3 March 2005 (03.03.2005)

PCT

(10) International Publication Number  
**WO 2005/019239 A2**

(51) International Patent Classification<sup>7</sup>: C07K

(21) International Application Number:  
PCT/US2004/023092

(22) International Filing Date: 16 July 2004 (16.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/488,415 18 July 2003 (18.07.2003) US

(71) Applicant (for all designated States except US):  
SMITHKLINE BEECHAM CORPORATION  
(US/US); One Franklin Plaza, Philadelphia, PA 19101  
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): COLLINS, Jon,


Loren [US/US]; GlaxoSmithKline, Five Moore Drive,  
PO Box 13398, Research Triangle Park, North Carolina  
27709 (US). LAMBERT, III, Millard, Hurst [US/US];  
GlaxoSmithKline, Five Moore Drive, PO Box 13398,  
Research Triangle Park, North Carolina 27709 (US).  
WISELY, George, Bruce [US/US]; GlaxoSmithKline,  
Five Moore Drive, PO Box 13398, Research Triangle Park,  
NC 27709 (US). XU, Robert [US/US]; GlaxoSmithKline,  
Five Moore Drive, PO Box 13398, Research Triangle Park,  
NC 27709 (US).

(74) Agents: LEVY, David, J. et al.; GlaxoSmithKline, Five  
Moore Drive, PO Box 13398, Research Triangle Park, NC  
27709 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,

[Continued on next page]

(54) Title: CAR LIGAND-BINDING DOMAIN POLYPEPTIDE CO-CRYSTALLIZED WITH A LIGAND, AND METHODS OF  
DESIGNING LIGANDS THAT MODULATE CAR ACTIVITY



(57) Abstract: The present invention provides a  
crystalline form of a substantially pure constitutive  
androstane receptor (CAR) polypeptide. Also  
provided is a crystalline form of a substantially pure  
constitutive androstane receptor (CAR) polypeptide  
in complex with a ligand. Also provided are  
methods for generating the crystalline forms of  
the present invention and methods for identifying  
and designing CAR ligands and modulators.  
Also provided are scalable three-dimensional  
configurations of points and computer readable  
storage media containing digitally encoded  
structural data

WO 2005/019239 A2